WFH/LinkedIn
Sep 18, 2025, 09:18
WFH Vice President Glenn Pierce on Slow Uptake and Industry Shifts in Hemophilia Gene Therapy
The World Federation of Hemophilia (WFH) posted on LinkedIn:
”WFH Vice President, Medical, Glenn Pierce, joins Zoey Becker in this week’s episode of The Top Line, to unpack the complex reality of Gene Therapy for hemophilia. Pierce discusses why the uptake remains slow, what led to some pharma companies exit and who risks being left behind in this evolving landscape.
Listen now.”
Stay updated with Hemostasis Today.
-
Aug 21, 2026, 12:34Kellie Machlus: Animal Models Driving Progress in Thrombosis Research
-
Aug 21, 2026, 12:08Amy Allen Whitfield: Helping to Proceed Bleeding Disorders Care
-
Aug 21, 2026, 11:53Jan Terje Andersen: Harnessing Placental Biology for Therapeutic Engineering
-
Aug 21, 2026, 11:02Severe ITP, Critical Bleeding, and the Challenge of Platelet Testing – RPTH Journal
-
Aug 21, 2026, 10:46Arwa Z. Al-Riyami: Looking Ahead to ISBT Muscat 2029
-
Aug 21, 2026, 10:42Janine Mothershed: What Is Romiplostim and How Does It Work in Immune Thrombocytopenia?
-
Aug 21, 2026, 10:33Omar Alkharabsheh: Excited to Build the Future of Hematologic Malignancy Care in Central Florida
-
Aug 21, 2026, 10:23Salvador Payán Pernía: Tailoring Therapy in Sickle Cell Disease – Mitapivat and the Path Toward Personalized Combination Care
-
Aug 21, 2026, 10:10Pete Stibbs: The Evolving Landscape of VTE Management